{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T02:32:55Z","timestamp":1780713175889,"version":"3.54.1"},"reference-count":59,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Atrial fibrillation (AF) is the most common arrhythmia in patients affected by cardiomyopathies. Reports estimate a prevalence of 27% in patients with hypertrophic cardiomyopathy (HCM) and 40% in patients with cardiac amyloidosis (CA). The presence of AF typically results in progressive functional decline, an increased frequency of hospitalizations for heart failure, and a higher thromboembolic risk. Medical management using mainly beta-blockers or amiodarone has produced variable outcomes and a high rate of recurrence. Catheter ablation reduces symptom burden and complications despite a moderate rate of recurrence. Recent evidence suggests that an early rhythm control strategy may lead to more favorable short- and long-term outcomes. In this review, we summarize contemporary data on the management of AF in patients with cardiomyopathy (HCM and CA) with particular reference to the timing and outcomes of ablation procedures.<\/jats:p>","DOI":"10.3390\/jcm13020501","type":"journal-article","created":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T08:12:37Z","timestamp":1705392757000},"page":"501","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy and Cardiac Amyloidosis: From Clinical Management to Catheter Ablation Indication"],"prefix":"10.3390","volume":"13","author":[{"given":"Raffaella","family":"Mistrulli","sequence":"first","affiliation":[{"name":"Clinical and Molecular Medicine Department, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7291-2450","authenticated-orcid":false,"given":"Armando","family":"Ferrera","sequence":"additional","affiliation":[{"name":"Clinical and Molecular Medicine Department, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melwyn Luis","family":"Muthukkattil","sequence":"additional","affiliation":[{"name":"Clinical and Molecular Medicine Department, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9195-5977","authenticated-orcid":false,"given":"Allegra","family":"Battistoni","sequence":"additional","affiliation":[{"name":"Clinical and Molecular Medicine Department, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4845-117X","authenticated-orcid":false,"given":"Giovanna","family":"Gallo","sequence":"additional","affiliation":[{"name":"Clinical and Molecular Medicine Department, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Barbato","sequence":"additional","affiliation":[{"name":"Clinical and Molecular Medicine Department, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Raffaele","family":"Spera","sequence":"additional","affiliation":[{"name":"Clinical and Molecular Medicine Department, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiano","family":"Magr\u00ec","sequence":"additional","affiliation":[{"name":"Clinical and Molecular Medicine Department, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC Guidelines on Diagnosis and Management of Hypertrophic Cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur. Heart J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1136\/heartjnl-2013-304276","article-title":"Atrial Fibrillation and Thromboembolism in Patients with Hypertrophic Cardiomyopathy: Systematic Review","volume":"100","author":"Guttmann","year":"2014","journal-title":"Heart"},{"key":"ref_3","first-page":"e533","article-title":"2020 AHA\/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"142","author":"Ommen","year":"2020","journal-title":"Circulation"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.echo.2004.02.010","article-title":"Left Atrial Volume and the Risk of Paroxysmal Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy","volume":"17","author":"Tani","year":"2004","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10741-018-9752-6","article-title":"Atrial Fibrillation in Hypertrophic Cardiomyopathy: Prevalence, Clinical Impact, and Management","volume":"24","author":"Garg","year":"2019","journal-title":"Heart Fail. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e001002","DOI":"10.1161\/JAHA.114.001002","article-title":"Atrial Fibrillation in Hypertrophic Cardiomyopathy: Prevalence, Clinical Correlations, and Mortality in a Large High-Risk Population","volume":"3","author":"Siontis","year":"2014","journal-title":"J. Am. Heart Assoc."},{"key":"ref_7","first-page":"672","article-title":"Predictors of Atrial Fibrillation in Hypertrophic Cardiomyopathy","volume":"103","author":"Guttmann","year":"2017","journal-title":"Heart Br. Card. Soc."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1161\/hc4601.097997","article-title":"Impact of Atrial Fibrillation on the Clinical Course of Hypertrophic Cardiomyopathy","volume":"104","author":"Olivotto","year":"2001","journal-title":"Circulation"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e009796","DOI":"10.1161\/CIRCEP.120.009796","article-title":"Development and Validation of a Clinical Predictive Model for Identifying Hypertrophic Cardiomyopathy Patients at Risk for Atrial Fibrillation: The HCM-AF Score","volume":"14","author":"Carrick","year":"2021","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1161\/STROKEAHA.119.026048","article-title":"Novel Oral Anticoagulants for Primary Stroke Prevention in Hypertrophic Cardiomyopathy Patients With Atrial Fibrillation","volume":"50","author":"Lee","year":"2019","journal-title":"Stroke"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.chest.2018.11.009","article-title":"Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation with Hypertrophic Cardiomyopathy: A Nationwide Cohort Study","volume":"155","author":"Jung","year":"2019","journal-title":"Chest"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1055\/s-0038-1676818","article-title":"Hypertrophic Cardiomyopathy in Patients with Atrial Fibrillation: Prevalence and Associated Stroke Risks in a Nationwide Cohort Study","volume":"119","author":"Jung","year":"2019","journal-title":"Thromb. Haemost."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1016\/j.jacc.2018.07.098","article-title":"Stroke Risk Stratification for Atrial Fibrillation Patients with Hypertrophic Cardiomyopathy","volume":"72","author":"Jung","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.amjcard.2019.02.051","article-title":"Safety, Side Effects and Relative Efficacy of Medications for Rhythm Control of Atrial Fibrillation in Hypertrophic Cardiomyopathy","volume":"123","author":"Miller","year":"2019","journal-title":"Am. J. Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation Developed in Collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the Diagnosis and Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Developed with the Special Contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.hjc.2022.05.002","article-title":"Atrial Fibrillation in Hypertrophic Cardiomyopathy\u2013A Contemporary Mini-Review","volume":"67","author":"Dragasis","year":"2022","journal-title":"Hell. J. Cardiol. HJC Hell. Kardiol. Ep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/j.jacc.2011.07.036","article-title":"Cardiovascular Outcomes in the AFFIRM Trial: An Assessment of Individual Antiarrhythmic Drug Therapies Compared to Rate Control Using Propensity Score Matched Analyses","volume":"58","author":"Saksena","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1161\/CIRCEP.113.000339","article-title":"Catheter Ablation of Atrial Fibrillation in Hypertrophic Cardiomyopathy: Long-Term Outcomes and Mechanisms of Arrhythmia Recurrence","volume":"6","author":"Santangeli","year":"2013","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"ref_19","first-page":"17","article-title":"Catheter Ablation of Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy: Atrial Fibrillation Type Determines the Success Rate","volume":"71","author":"Derejko","year":"2013","journal-title":"Kardiol. Pol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.hrthm.2015.03.042","article-title":"Outcomes of Nonpharmacologic Treatment of Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy","volume":"12","author":"Bassiouny","year":"2015","journal-title":"Heart Rhythm."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/jce.14880","article-title":"Transcatheter Ablation for Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy: Long-Term Results and Clinical Outcomes","volume":"32","author":"Castagno","year":"2021","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e017451","DOI":"10.1161\/JAHA.120.017451","article-title":"Ablation of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy: Treatment Strategy, Characteristics of Consecutive Atrial Tachycardia and Long-Term Outcome","volume":"10","author":"Dinshaw","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/europace\/euq013","article-title":"Efficacy of Catheter Ablation for Atrial Fibrillation in Hypertrophic Cardiomyopathy: Impact of Age, Atrial Remodelling, and Disease Progression","volume":"12","author":"Olivotto","year":"2010","journal-title":"Europace"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1093\/ejcts\/ezx017","article-title":"Mid-Term Outcomes of Concomitant Surgical Ablation of Atrial Fibrillation in Patients Undergoing Cardiac Surgery for Hypertrophic Cardiomyopathy","volume":"51","author":"Lapenna","year":"2017","journal-title":"Eur. J. Cardio Thoracic Surg."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"720950","DOI":"10.3389\/fcvm.2021.720950","article-title":"Clinical Efficacy and Safety of Cox-Maze IV Procedure for Atrial Fibrillation in Patients With Hypertrophic Obstructive Cardiomyopathy","volume":"8","author":"Meng","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1111\/jocs.14946","article-title":"Surgical Ablation of Atrial Fibrillation in Hypertrophic Obstructive Cardiomyopathy: Outcomes of a Tailored Surgical Approach","volume":"35","author":"Hodges","year":"2020","journal-title":"J. Card. Surg."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"386","DOI":"10.21037\/acs.2017.05.08","article-title":"Surgical Management of Atrial Fibrillation at the Time of Septal Myectomy","volume":"6","author":"Quintana","year":"2017","journal-title":"Ann. Cardiothorac. Surg."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and Treatment of Cardiac Amyloidosis: A Position Statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Rapezzi","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/joim.13169","article-title":"Systemic Amyloidosis from A (AA) to T (ATTR): A Review","volume":"289","author":"Muchtar","year":"2021","journal-title":"J. Intern. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/europace\/euv339","article-title":"Outcomes of Catheter Ablation of Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis","volume":"18","author":"Zhao","year":"2016","journal-title":"Europace"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Laptseva, N., Rossi, V.A., Sudano, I., Schwotzer, R., Ruschitzka, F., Flammer, A.J., and Duru, F. (2023). Arrhythmic Manifestations of Cardiac Amyloidosis: Challenges in Risk Stratification and Clinical Management. J. Clin. Med., 12.","DOI":"10.3390\/jcm12072581"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e005407","DOI":"10.1161\/CIRCHEARTFAILURE.118.005407","article-title":"Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States","volume":"12","author":"Gilstrap","year":"2019","journal-title":"Circ. Heart Fail."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3109\/13506129.2015.1028616","article-title":"Atrial Fibrillation in Amyloidotic Cardiomyopathy: Prevalence, Incidence, Risk Factors and Prognostic Role","volume":"22","author":"Longhi","year":"2015","journal-title":"Amyloid"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/ehf2.13851","article-title":"Clinical Features and Predictors of Atrial Fibrillation in Patients with Light-Chain or Transthyretin Cardiac Amyloidosis","volume":"9","author":"Papathanasiou","year":"2022","journal-title":"ESC Heart Fail."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nrcardio.2014.165","article-title":"Pathophysiology and Treatment of Cardiac Amyloidosis","volume":"12","author":"Gertz","year":"2015","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1002\/ejhf.2650","article-title":"Atrial Amyloidosis: Mechanisms and Clinical Manifestations","volume":"24","author":"Vergaro","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"ref_37","first-page":"1128","article-title":"Left Atrial Structure and Function in Cardiac Amyloidosis","volume":"18","author":"Nochioka","year":"2017","journal-title":"Eur. Heart J. Cardiovasc. Imag."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jcmg.2021.06.022","article-title":"Clinical Importance of Left Atrial Infiltration in Cardiac Transthyretin Amyloidosis","volume":"15","author":"Bandera","year":"2022","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/eurheartj\/ehm351","article-title":"Atrial Enhancement by Cardiovascular Magnetic Resonance in Cardiac Amyloidosis","volume":"29","author":"Lyne","year":"2008","journal-title":"Eur. Heart J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/eurheartj\/ehi766","article-title":"Atrial Pathology in Cardiac Amyloidosis: Evidence from ECG and Cardiovascular Magnetic Resonance","volume":"27","author":"Leeson","year":"2006","journal-title":"Eur. Heart J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"ehac544-1787","DOI":"10.1093\/eurheartj\/ehac544.1787","article-title":"Incidence and Factors Associated with de Novo Atrial Fibrillation in Patients with Wild-Type Transthyretin Cardiac Amyloidosis","volume":"43","author":"Fumagalli","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1080\/13506129.2019.1620724","article-title":"Atrial Fibrillation and Subtype of Atrial Fibrillation in Cardiac Amyloidosis: Clinical and Echocardiographic Features, Impact on Mortality","volume":"26","author":"Sanchis","year":"2019","journal-title":"Amyloid"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.jacep.2020.04.019","article-title":"Atrial Fibrillation in Transthyretin Cardiac Amyloidosis: Predictors, Prevalence, and Efficacy of Rhythm Control Strategies","volume":"6","author":"Donnellan","year":"2020","journal-title":"JACC Clin. Electrophysiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1056\/NEJM199211263272205","article-title":"Brief Report: Atrial Systolic Failure in Primary Amyloidosis","volume":"327","author":"Plehn","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"ehad194","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC Guidelines for the Management of Cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.jacep.2019.10.013","article-title":"No Association Between CHADS-VASc Score and Left Atrial Appendage Thrombus in Patients With Transthyretin Amyloidosis","volume":"5","author":"Donnellan","year":"2019","journal-title":"JACC Clin. Electrophysiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"101188","DOI":"10.1016\/j.cpcardiol.2022.101188","article-title":"Effectiveness and Safety of Oral Anticoagulants in Cardiac Amyloidosis: Lights and Shadows","volume":"48","author":"Damerino","year":"2023","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Briasoulis, A., Kourek, C., Papamichail, A., Loritis, K., Bampatsias, D., Repasos, E., Xanthopoulos, A., Tsougos, E., and Paraskevaidis, I. (2023). Arrhythmias in Patients with Cardiac Amyloidosis: A Comprehensive Review on Clinical Management and Devices. J. Cardiovasc. Dev. Dis., 10.","DOI":"10.3390\/jcdd10080337"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","article-title":"Transthyretin (TTR) Cardiac Amyloidosis","volume":"126","author":"Ruberg","year":"2012","journal-title":"Circulation"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e12749","DOI":"10.1111\/anec.12749","article-title":"Autonomic Dysfunction in Cardiac Amyloidosis Assessed by Heart Rate Variability and Heart Rate Turbulence","volume":"25","author":"Yamada","year":"2020","journal-title":"Ann. Noninvasive Electrocardiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/0002-9149(85)90996-8","article-title":"Selective Binding of Nifedipine to Amyloid Fibrils","volume":"55","author":"Gertz","year":"1985","journal-title":"Am. J. Cardiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"989","DOI":"10.7326\/0003-4819-55-6-989","article-title":"Cardiac Amyloidosis. Two Cases with Digitalis Sensitivity","volume":"55","author":"Cassidy","year":"1961","journal-title":"Ann. Intern. Med."},{"key":"ref_54","unstructured":"Assaf, A., Mekhael, M., Noujaim, C., Chouman, N., Younes, H., Kreidieh, O., Marrouche, N., and Donnellan, E. (2023). Trends in Cardiovascular Medicine, Elsevier."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.hrthm.2015.09.016","article-title":"Electrophysiologic Assessment of Conduction Abnormalities and Atrial Arrhythmias Associated with Amyloid Cardiomyopathy","volume":"13","author":"Barbhaiya","year":"2016","journal-title":"Heart Rhythm"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/jce.13046","article-title":"Catheter Ablation for Atrial Arrhythmias in Patients With Cardiac Amyloidosis","volume":"27","author":"Tan","year":"2016","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/europace\/euz314","article-title":"Atrial Fibrillation Ablation in Patients with Transthyretin Cardiac Amyloidosis","volume":"22","author":"Donnellan","year":"2020","journal-title":"Eurospace"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e029339","DOI":"10.1161\/JAHA.122.029339","article-title":"Safety of Catheter Ablation Therapy for Atrial Fibrillation in Cardiac Amyloidosis","volume":"12","author":"Alhassan","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"oead026","DOI":"10.1093\/ehjopen\/oead026","article-title":"Adverse Outcomes of Atrial Fibrillation Ablation in Heart Failure Patients with and without Cardiac Amyloidosis: A Nationwide Readmissions Database Analysis (2015\u20132019)","volume":"3","author":"Ullah","year":"2023","journal-title":"Eur. Heart J. Open"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/2\/501\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:47:58Z","timestamp":1760104078000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/2\/501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,16]]},"references-count":59,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["jcm13020501"],"URL":"https:\/\/doi.org\/10.3390\/jcm13020501","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,16]]}}}